• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Study: FDA should have banned pelvic mesh long before it did

Study: FDA should have banned pelvic mesh long before it did

February 19, 2020 By Nancy Crotti

FDAResearchers who conducted a long-term study of women implanted with transvaginal mesh to treat pelvic organ prolapse (POP) concluded that the FDA should have banned the product sooner than it did.

The study of 54,194 women in New York State revealed that women treated with mesh had an 8.8% risk of reintervention 5 years after surgery, compared with 6.3% in the same size group of women treated differently for the same condition. This 40% increased risk was observed across all levels of hospital volume in performing POP procedures, the researchers reported.

The observational study paired more than 12,000 women in each group and is a follow-up to the same researchers’ review of patients 12 months after implantation. The research team — which included medical doctors from Weill Cornell Medical College-New York Presbyterian in New York, the University of Oxford in the UK, the Warren Alpert Medical School of Brown University in Rhode Island, and the Women & Infants Hospital in Providence, R.I. — published their results in the journal Obstetrics & Gynecology.

The governments of Scotland and the UK noted the risks to women of pelvic mesh in 2017, with the UK National Institute for Health and Care Excellence concluding that these procedures should be confined to research. Health officials in Australia and New Zealand effectively banned the mesh their markets that same year.

The FDA reported more than 1,000 adverse events related to pelvic mesh in 2008, and reclassified the product from moderate-risk Class II designation to high-risk Class III in 2016. Postmarket studies the FDA requested from mesh manufacturers beginning in 2012 failed to attract enough participation from surgeons, the researchers reported. The agency ordered manufacturers to stop selling the product in the U.S. in April 2019, citing a lack of manufacturers providing “reasonable assurance” of the long-term safety and effectiveness using the mesh for POP.

“The United States was late in the removal of mesh implants for POP despite the numerous safety warnings and adverse events reported from patients’ narratives,” the researchers said. “Even though transvaginal mesh has been removed from the market, our data suggest that the risk of mesh complications does not diminish over time and these women warrant close follow-up.”

The FDA’s April 2019 order was the culmination of a multi-year regulatory process required by statute, according to an agency spokesperson. The agency said it 131 postmarket surveillance study orders in 2012 to 34 manufacturers, requiring them to collect data to address specific safety and effectiveness. Most manufacturers opted to stop manufacturing transvaginal mesh.

After the FDA reclassified the devices to Class III, requiring premarket authorization, multiple PMAs were submitted and the regulatory process allowed continued marketing of such products during the agency’s review, the spokesperson said in an email to MassDevice. None of the companies demonstrated a reasonable assurance of safety and effectiveness for their devices.

“All along, the FDA has been transparent about our concerns with the public,” the spokesperson added. “The FDA issued safety communications in 2008 and 2011 based on our review of reports of complications and held public panel meetings in 2011 and 2019 where safety and effectiveness was discussed openly with experts. Our goal was to keep patients informed of the risks of these products while we moved through our multi-year regulatory process.”

In the new study, 18.5% of mesh patients who had reinterventions underwent a procedure for mesh-related complications, with the remaining 81.5% receiving reinterventions related to new or recurrent prolapse, urinary complications and other reasons.

The results also controverted the traditional belief that mesh procedures reduce the recurrence of POP through good apical support, the authors said. Their findings showed a higher rate of repeat POP surgery overall in women with mesh (652 patients or 5.3% of all patients) than in women without mesh (513 patients or 4.2% of all patients).

Complications reported from pelvic mesh include chronic inflammation, mesh shrinkage and embedding in scar tissue, infection, bleeding, pain during sexual intercourse, organ perforation, protrusion through the vaginal wall and urinary problems. Mesh manufacturers have paid millions of dollars in legal judgments and settlements, and the lawsuits keep coming.

The researchers said mesh erosion appears to present an “ongoing risk,” as they found no decline in mesh erosion rates over the study period. The rates they discovered almost double those published by a Cochrane Review in 2016, in which only 8% of repeat surgical interventions were for mesh-related complications. That study covered 37 randomized controlled trials following 4,023 women, comparing outcomes for pelvic mesh with native tissue repair for POP.

“This rate of mesh complication may actually be underestimated given that only women who underwent reintervention are captured and not any of the women who had mesh erosions and complications that were conservatively managed in the office setting,” the researchers in the new study said.

“Continued surveillance of mesh in POP repairs is essential to ensure safety for the women who have already been implanted,” they concluded. “Registries should include comprehensive information about the nature and burden of POP recurrence, different types of re-treatment, patient-reported outcomes, and information about implanting surgeons.”

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Gynecological, Regulatory/Compliance, Women's Health Tagged With: FDA, pelvic mesh

In case you missed it

  • FDA clears VySpine’s VyPlate anterior cervical plate system
  • Technical Brief – “Understanding the Extensive OEM Benefits of Total Linear Motion Solutions.”
  • Exactech launches total hip arthroplasty system
  • Lensar announces first patients treated with Ally adaptive cataract treatment
  • HeartBeam submits heart attack diagnostic platform for FDA 510(k) clearance
  • GE Healthcare leads AliveCor Series F funding for ECG tech
  • New FDA ruling may lower costs for over-the-counter hearing aids
  • Data supports Sight Sciences’ Omni surgical system for glaucoma
  • Integra founder Richard Caruso has died
  • Moximed raises $40M for implantable shock absorber for knee osteoarthritis
  • Philips names Roy Jakobs as CEO amid ventilator, CPAP recalls
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio
  • Outset Medical wins national VA contract
  • Inspire Medical Systems appoints former Zimmer Biomet exec as VP of investor relations
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results

RSS From Medical Design & Outsourcing

  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy